RxDoctor Payments Data

Stephen Wolchok, MD

Ophthalmology · Jacksonville, FLNPI 1740324102

Payments from drug & device makers

$1,643in general payments, 2019–2025

Across 38 payments — averaging $43.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$360
  • Lumenis BE Inc$321
  • Glaukos Corporation$296
  • Halozyme Inc$191
  • Amgen$159
  • Johnson & Johnson Surgical Vision, Inc.$146
  • plus $168 from 6 others

What the payments were for

  • Food & beverage$1,643100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,643 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$376,612
Medicare patients
1,182
Services billed
3,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine70$74,325
Restasis MultidoseCyclosporine19$12,959
LumiganBimatoprost15$10,926
RocklatanNetarsudil Mesylat/Latanoprost24$10,726
Latanoprost809$10,502
XiidraLifitegrast12$9,847
VyzultaLatanoprostene Bunod19$9,056
SimbrinzaBrinzolamide/Brimonidine Tart35$8,272
Difluprednate59$5,317
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat195$3,843
Travoprost22$3,245
Tobramycin-DexamethasoneTobramycin/Dexamethasone84$3,211
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$2,776
Prednisolone Acetate91$2,707
TafluprostTafluprost/Pf21$2,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$24$18,90331 claims
AlconSimbrinza$360$8,27235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →